Evaluation of efficacy and prognosis of adult diffuse large B-cell lymphoma based on the LymphGen typing
Objective To investigate the relationship between molecular genetic characteristics,clinical pathological features,curative effect and prognosis of adult diffuse large B-cell lymphoma(DLBCL)by LymphGen typing,and to verify the guiding value of genotyping for the prognosis and treatment of DLBCL.Methods The clinical and pathological data of 130 patients with untreated adult DLBCL with complete data were collected from the First Affiliated Hospital of Anhui Medical University,including the results of lympho-ma-related immunofluorescence in situ hybridization and next-generation sequencing.The detection results were grouped according to LymphGen typing,and the Kaplan-Meier method was used to draw survival curves to analyze the relationship between genotypes and clinicopathological characteristics,as well as the effect of genotypes on efficacy,progression-free survival(PFS)and overall survival(OS).Results A total of 69 cases(53.1％)of the 130 patients could be genotyped by LymphGen.Among them,the distribution of cell origin classification and lymphoma international prognostic index(IPI)was different among gene subtypes,and the differences were statistically significant(P=0.0350,0.041).The source of non-germinal center B cells were more common in MCD and A53 types,and most of them had relatively high IPI scores,and poor efficacy,PFS and OS.The survival curve and test results showed that there was a significant difference in 5-year PFS rate between different gene subtypes(P=0.008),but there was no significant difference in 5-year OS rate(P=0.279).Conclusion The genetic subtypes of LymphGen genetic subtypes have a certain guiding value for the progno-sis and treatment of DLBCL,among which the MCD and A53 groups have poorer efficacy and prognosis.
Diffuse large B-cell lymphomaGenotypingNext-generation sequencingMutationPrognosis
万方数据
维普
